Metagenomi
Berkeley, US · Founded 2018 · 20 known investors
Find your way into Metagenomi
929 people in our graph share verified history with the Metagenomi team — schools, employers, funds. One of them is your warm intro.
Scott Davisunlockedknows Brian Thomas · together at University of California, Berkeley (overlapped)
×11knows the team · via University of California, Berkeley
Metagenomi Therapeutics is an in vivo genome editing company that uses genetic material sourced from natural environments (metagenomics) to develop a toolbox of editing tools for deletion, integration, and correction of genetic mutations. It focuses on developing genetic medicines to treat diseases with well-understood biology.
Founders & leadership
Metagenomi was founded in 2018 by Brian Thomas.
BT
Brian ThomasinFounder · DirectorBrian Thomas is Executive Officer and Director at Metagenomi Therapeutics, an in vivo genome editing company developing genetic medicines to treat diseases with well-understood biology.
Board
AF
Andrew FarquharsonBoard director
JK
Jak KnowlesBoard director
Investors · 20
Catalio Capital Management, LPNew York
RA CapitalBoston
Sozo VenturesRedwood City
Agent Capitalreported · 2 sourcesWaltham
Frazier Life SciencesreportedPalo Alto
Humboldtreported · 2 sourcesNew York · $100K – $5M
InCube VenturesreportedSan Jose
Irving InvestorsreportedNew York
Leaps by Bayerreported · 2 sourcesLeverkusen
Novo HoldingsreportedCopenhagen · $1.1M – $54M
Pura Vida InvestmentsreportedNew York
VHMreportedSan Jose
Also in the syndicate · 8
Bristol Myers SquibbDeep Track CapitalEventide Asset ManagementFarallon Capital ManagementleadHumboldt FundLeapsModernaPFM Health Scienceslead
Reported raises · per SEC filings
Form D private placements$345.1M disclosed across 5 rounds · 2019–2022
▶$95.8MraisedJan 2023 · 25 investors · BiotechnologyRule 506(b)
▶$95.8MraisedJan 2023 · 25 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Willard DereDirector
- Brian C. ThomasExecutive Officer, Director
- Santhosh PalaniDirector
- Risa StackDirector
- Juergen EckhardtDirector
- Sebastian BernalesDirector
- Offering amount
- $100M
- Amount sold
- $95.8M
- Minimum investment
- $100K
- First sale
- Dec 2022
- Incorporated
- Limited Liability Company, Delaware, 2018
- Federal exemptions
- 06b
▶$175.4MraisedFeb 2022 · 29 investors · BiotechnologyRule 506(b)
▶$175.4MraisedFeb 2022 · 29 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Risa StackDirector
- Brian ThomasExecutive Officer, Director
- Willard DereDirector
- Juergen EckhardtDirector
- Sebastian BernalesDirector
- Santosh PalaniDirector
- Offering amount
- $175.4M
- Amount sold
- $175.4M
- Minimum investment
- $1M
- First sale
- Jan 2022
- Incorporated
- Limited Liability Company, Delaware, 2018
- Federal exemptions
- 06b
▶$10MraisedMar 2021 · 2 investors · BiotechnologyRule 506(b)
▶$10MraisedMar 2021 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Andrew LevinDirector
- Sebastian BernalesDirector
- Andrew FarquharsonDirector
- Brian ThomasExecutive Officer, Director, Promoter
- Juergen EckhardtDirector
- Offering amount
- $10M
- Amount sold
- $10M
- First sale
- Mar 2021
- Incorporated
- Limited Liability Company, Delaware, 2018
- Federal exemptions
- 06b
▶$37.5MraisedNov 2020 · 11 investors · Other TechnologyRule 506(b)
▶$37.5MraisedNov 2020 · 11 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Brian ThomasExecutive Officer, Director, Promoter
- Sebastian BernalesDirector
- Andrew FarquharsonDirector
- Juergen EckhardtDirector
- Offering amount
- $40.2M
- Amount sold
- $37.5M
- First sale
- Nov 2020
- Incorporated
- Limited Liability Company, Delaware, 2018
- Federal exemptions
- 06b
▶$26.4MraisedAug 2019 · 16 investors · Other TechnologyRule 506(b)
▶$26.4MraisedAug 2019 · 16 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Brian ThomasExecutive Officer, Director, Promoter
- Andrew FarquharsonDirector
- Jak KnowlesDirector
- Offering amount
- $27.3M
- Amount sold
- $26.4M
- First sale
- Aug 2019
- Incorporated
- Limited Liability Company, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
3 people who came through Metagenomi went on to found or lead other companies.
In the news
Metagenomi Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results | The Manila Timesmanilatimes.net · Aug 2026Frequently asked questions
- What does Metagenomi do?
- Metagenomi Therapeutics is an in vivo genome editing company that uses genetic material sourced from natural environments (metagenomics) to develop a toolbox of editing tools for deletion, integration, and correction of genetic mutations. It focuses on developing genetic medicines to treat diseases with well-understood biology.
- Who founded Metagenomi?
- Metagenomi was founded by Brian Thomas in 2018.
- Who are Metagenomi's investors?
- Metagenomi's investors include Catalio Capital Management, LP, RA Capital, Sozo Ventures, Agent Capital, Frazier Life Sciences, Humboldt, InCube Ventures, Irving Investors and 4 more.
- How much funding has Metagenomi raised?
- Metagenomi has disclosed $345.1M raised across 5 rounds.
- Where is Metagenomi headquartered?
- Metagenomi is headquartered in Berkeley, US.